EP PerMed , JTC2024 (1 konkurs)

The core of each application must be the identification or validation of a target for personalised medicine approaches in combination with companion biomarker research. In addition, the consortia can address accompanying research if this is necessary for the identification or validation of the target and if appropriate to the development status of the project.

Depending on the development phase of the research, projects can focus on the following stages

Stage 1: Identification of novel targets for the development of a concrete and feasible PM approach, based on a clearly circumscribed biological/clinical hypothesis, in combination with companion biomarker research. Applicants are advised to use existing clinical data as a basis for target identification.

Stage 2: Development or validation of already known but not yet established targets for a PM approach, in combination with accompanying biomarker research. This includes target validation in vitro and in animal models (proof-of-principle studies), early pharmacological and toxicity tests and, if feasible, exploratory clinical studies to demonstrate clinical applicability (proof-of-concept studies).

Exclusion: Research focussing only on new biomarker discovery. Projects submitted to the JTC2024 focussing on the identification of new biomarkers as the sole purpose of the research are out of the scope.

Research projects in all disease areas are encouraged.

Alokacja dla polskich podmiotów wynosi  1 100 000EUR.

Harmonogram konkursu: